The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma-Reference-Cited by-同舟云学术

The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma

Published:2003-01-24 Issue:1 Volume:25 Page:41-46
ISSN:0141-9854
Container-title:Clinical & Laboratory Haematology
language:en
Short-container-title:

Author:

Alexandrakis M.G.,Passam F.H.,Ganotakis E.S.,Sfiridaki K.,Xilouri I.,Perisinakis K.,Kyriakou D.S.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2257.2003.00492.x/fullpdf

Reference26 articles.

1. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6;Bataille;Blood,1989

2. C-reactive protein and beta 2 microglobulin produce a simple and powerful myeloma staging system;Bataille;Blood,1992

3. Cytokine regulation of the acute phase protein levels in multiple myeloma;Biro;Eur J Clin Invest,1998

4. The use of a commercial available immunoassay to determine the level of interleukin-6 in the serum of patients with multiple myeloma;Brown;Leuk Lymphoma,1991

5. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes;Castell;FEBS Lett,1989

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Modern Bone Markers in Multiple Myeloma: Prospective Analyses Pre and Post-First Line Treatment;Current Issues in Molecular Biology;2024-08-24

2. Serum levels of interleukin-10 and its receptor in the multiple myeloma type I patients;Journal of Research in Applied and Basic Medical Sciences;2023-10-01

3. Diagnostic and Prognostic Value of PACAP in Multiple Myeloma;International Journal of Molecular Sciences;2023-06-28

4. Circulating biosignatures in multiple myeloma and their role in multidrug resistance;Molecular Cancer;2023-04-29

5. MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation;BMC Cancer;2023-03-03